Patents by Inventor Joel Renick

Joel Renick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted azetidinyl compounds as GlyT1 inhibitors
    Patent number: 10040759
    Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: August 7, 2018
    Assignee: Dart NeuroScience (Cayman) Ltd.
    Inventors: Jillian Basinger, Brett Bookser, Mi Chen, Andrew Hudson, James Na, Joel Renick, Vincent Santora
  • SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS
    Publication number: 20170334846
    Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.
    Type: Application
    Filed: November 3, 2015
    Publication date: November 23, 2017
    Applicant: Dart Neuroscience (Cayman) Ltd.
    Inventors: Jillian Basinger, Brett Bookser, Mi Chen, Andrew Hudson, James Na, Joel Renick, Vincent Santora
  • Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors
    Patent number: 9708334
    Abstract: The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, R4, R5 and X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: July 18, 2017
    Assignee: Dart NeuroScience (Cayman) Ltd.
    Inventors: Jillian Basinger, Brett Bookser, Mi Chen, DeMichael Chung, Varsha Gupta, Andrew Hudson, Alan Kaplan, James Na, Joel Renick, Vincent Santora
  • SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS
    Publication number: 20170044167
    Abstract: The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, R4, R5 and X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.
    Type: Application
    Filed: April 22, 2015
    Publication date: February 16, 2017
    Inventors: Jillian Basinger, Brett Bookser, Mi Chen, DeMichael Chung, Varsha Gupta, Andrew Hudson, Alan Kaplan, James Na, Joel Renick, Vincent Santora
  • Therapeutic 5,6,5-tricyclic analogs
    Patent number: 9012470
    Abstract: The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and negatively modulating the ?5 subtype of GABAA, and use of the compound of formula I in the manufacture of a medicament for the treatment of GABAA receptor associated disorders. The invention further provides a method of modulation of one or more GABAA subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: April 21, 2015
    Assignee: Dart NeuroScience (Cayman) Ltd.
    Inventors: Varsha Gupta, Joel Renick, Graeme Freestone, Alan P. Kaplan
  • Bi-aryl meta-pyrimidine inhibitors of kinases
    Patent number: 8604042
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: December 10, 2013
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll
  • Benzotriazine inhibitors of kinases
    Patent number: 8481536
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: July 9, 2013
    Assignee: TargeGen, Inc.
    Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Glenn Noronha, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Binqi Zeng, Ningning Zhao, Elena Dneprovskaia
  • Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas
    Publication number: 20120129893
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 24, 2012
    Inventors: Jacques DUMAS, Uday Khire, Timothy B. Lowinger, Holger Paulsen, Bernd Riedl, William J. Scott, Roger A. Smith, Jill E. Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Wendy Lee, Aniko Redman, Robert Sibley, Joel Renick
  • THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS
    Publication number: 20120095016
    Abstract: The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and negatively modulating the ?5 subtype of GABAA, and use of the compound of formula I in the manufacture of a medicament for the treatment of GABAA receptor associated disorders. The invention further provides a method of modulation of one or more GABAA subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).
    Type: Application
    Filed: October 11, 2011
    Publication date: April 19, 2012
    Applicant: Helicon Therapeutics, Inc.
    Inventors: Varsha Gupta, Joel Renick, Graeme Freestone, Alan P. Kaplan
  • OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
    Publication number: 20120040986
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: August 11, 2011
    Publication date: February 16, 2012
    Inventors: Bernd RIEDL, Jacques DUMAS, Uday KHIRE, Timothy B. LOWINGER, William J. SCOTT, Roger A. SMITH, Jill E. WOOD, Mary-Katherine MONAHAN, Reina NATERO, Joel RENICK, Robert N. SIBLEY
  • BENZOTRIAZINE INHIBITORS OF KINASES
    Publication number: 20110294796
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: December 28, 2010
    Publication date: December 1, 2011
    Applicant: TargeGen, Inc.
    Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Ningning Zhao, Elena Dneprovskaia, Binqi Zeng, Glenn Noronha
  • 2-amino—5-substituted pyrimidine inhibitors
    Patent number: 8030487
    Abstract: Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: October 4, 2011
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Jianguo Cao, Colleen Gritzen, Chi Ching Mak, Andrew McPherson, Ved P. Pathak, Joel Renick, Richard M. Soll, Binqi Zeng, Elena Dneprovskaia
  • BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES
    Publication number: 20110212077
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: August 24, 2010
    Publication date: September 1, 2011
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll
  • Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
    Patent number: 7928239
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: April 19, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Jill E. Wood, Robert N. Sibley, Mary-Katherine Monahan, Joel Renick, David E. Gunn, Timothy B. Lowinger, William J. Scott, Roger A. Smith
  • ?-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
    Patent number: 7897623
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: March 1, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Bernd Riedl, Jacques Dumas, Uday R. Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Bi-aryl meta-pyrimidine inhibitors of kinases
    Patent number: 7825246
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: November 2, 2010
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll
  • INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS
    Publication number: 20100160371
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: November 17, 2009
    Publication date: June 24, 2010
    Inventors: Gerald RANGES, William Scott, Michael Bombara, Deborah Rauner, Aniko Redman, Roger Smith, Holger Paulsen, David Gunn, Jinshan Chen, Joel Renick
  • Benzotriazine Inhibitors of Kinases
    Publication number: 20090275569
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: September 9, 2008
    Publication date: November 5, 2009
    Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Glenn Noronha, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Ningning Zhao, Elena Dneprovskaia, Binqi Zeng, Glenn Noronha
  • OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
    Publication number: 20090118268
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 10, 2008
    Publication date: May 7, 2009
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Bi-aryl meta-pyrimidine inhibitors of kinases
    Patent number: 7528143
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: May 5, 2009
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll